EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TFAP2C drives cisplatin resistance in bladder cancer by upregulating YAP and activating β-catenin signaling

Qiufeng Pan, Changmin Zou, Zhigen Lin, Hao Tang, Zepu Long, Longwang Wang

Journal of Biological Chemistry · 2025

DOI: 10.1016/j.jbc.2025.110387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Qiufeng Pan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Cisplatin, Transcription Factor AP-2, Urinary Bladder Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The natural Science Foundation Project of Jiangxi Province, Natural Science Foundation of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin-based chemotherapy is a conventional therapy for muscle-invasive bladder cancer (BC); however, its efficacy is often limited by the emergence of resistance to cisplatin. Yes-associated protein (YAP) and β-catenin are involved in this resistance, yet their upstream regulators are not well defined. This study investigates the role of TFAP2C in regulating YAP expression and its impact on cisplatin resistance in BC. The Cancer Genome Atlas (TCGA) gene expression data and GSE231835 dataset were analyzed to identify potential transcription factors regulating YAP. Assessed TFAP2C and YAP expression in clinical samples and cell lines. Functional assays were performed following TFAP2C knockdown. Dual-luciferase reporter assays and Chromatin immunoprecipitation (ChIP) confirmed TFAP2C binding to the YAP promoter. A mouse model evaluated the effects of TFAP2C silencing on tumor growth and cisplatin resistance. The results showed that TFAP2C was identified as an upstream activator of YAP, with elevated expression in cisplatin-resistant BC cell lines and positive correlation with YAP expression. Silencing TFAP2C reduced malignant behaviors, decreased YAP, phosphorylated YAP (p-YAP) and β-catenin levels, and increased apoptosis in both cisplatin-sensitive and cisplatin-resistant BC cells. Besides, TFAP2C directly binds to the YAP promoter, enhancing its transcription. In the xenograft model, TFAP2C silencing significantly inhibited tumor growth and reduced cisplatin resistance. TFAP2C promotes cisplatin resistance and malignant behavior in BC by upregulating YAP and activating the β-catenin signaling pathway. Targeting TFAP2C offers a novel therapeutic strategy to overcome cisplatin resistance in BC, representing a new discovery in combating chemoresistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinTranscription Factor AP-2Urinary Bladder NeoplasmsDrug Resistance, Neoplasmbeta CateninAdaptor Proteins, Signal TransducingTranscription FactorsUp-RegulationHumansAnimalsYAP-Signaling ProteinsMiceCell Line, TumorGene Expression Regulation, NeoplasticSignal TransductionMice, NudeAntineoplastic Agents

Stichwörter der Autor:innen

YAPbladder cancercisplatin resistancetranscription regulationβ-catenin

Substanzen

CisplatinTranscription Factor AP-2beta CateninYAP-Signaling ProteinsYAP1 protein, humanAdaptor Proteins, Signal TransducingTFAP2C protein, humanTranscription FactorsCTNNB1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Urology, Taihe County People's Hospital, JiAn, China.
  • The First Clinical Medical College, Nanchang University, Nanchang, China.
  • Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Electronic address: ndyfy05787@ncu.edu.cn.

Förderung

  • The natural Science Foundation Project of Jiangxi Province
  • Natural Science Foundation of Jiangxi Province

Zitieren

APA

Pan, Q., Zou, C., Lin, Z., Tang, H., Long, Z., & Wang, L. (2025). TFAP2C drives cisplatin resistance in bladder cancer by upregulating YAP and activating β-catenin signaling. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110387

Vancouver

Pan Q, Zou C, Lin Z, Tang H, Long Z, Wang L. TFAP2C drives cisplatin resistance in bladder cancer by upregulating YAP and activating β-catenin signaling. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110387

BibTeX
@article{Pan2025,
  author = {Pan, Qiufeng and Zou, Changmin and Lin, Zhigen and Tang, Hao and Long, Zepu and Wang, Longwang},
  title = {TFAP2C drives cisplatin resistance in bladder cancer by upregulating YAP and activating β-catenin signaling},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.110387}
}
Kostenlos starten →